CYP2C8

Cytochrome P450 2C8 · P10632 · CYP2C8 on Sugi Atlas →

149,426 patent compounds predicted against CYP2C8, 115,776 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Amodiaquine (SCHEMBL44152)	0.98	6/20
Gingerol (SCHEMBL32102)	1.00	4/20
Shogaol (SCHEMBL49054)	1.00	4/20
SCHEMBL32090	0.72	4/20
SCHEMBL87584	0.40	4/20
Allylbenzene (SCHEMBL44762)	0.41	3/20
Omeprazole (SCHEMBL1192)	0.40	3/20
Esomeprazole (SCHEMBL19535)	0.40	3/20
Montelukast (SCHEMBL4486)	1.00	2/20
Montelukast (SCHEMBL4487)	1.00	2/20
Gemfibrozil (SCHEMBL4813)	1.00	2/20
Montelukast (SCHEMBL9414)	1.00	2/20
Montelukast (SCHEMBL9415)	1.00	2/20
Montelukast (SCHEMBL41733)	0.99	2/20
Montelukast (SCHEMBL8293)	0.77	2/20
1,3,5-Trimethoxybenzene (SCHEMBL28493)	0.55	2/20
Ciglitazone (SCHEMBL38185)	0.51	2/20
SCHEMBL3222	0.50	2/20
SCHEMBL12501	0.46	2/20
SCHEMBL21263	0.44	2/20

Clinical trials — most relevant to CYP2C8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.	PHASE3	ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial	PHASE3	ACTIVE_NOT_RECRUITING
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults	PHASE2	RECRUITING
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer	PHASE2	ACTIVE_NOT_RECRUITING
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma	PHASE2	COMPLETED
3 Month PHI PAD PoM Study	PHASE2	COMPLETED
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer	PHASE2	RECRUITING
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer	PHASE2	RECRUITING
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours	PHASE2	COMPLETED
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis	PHASE2	COMPLETED
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer	PHASE2	WITHDRAWN
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL	PHASE2	RECRUITING
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.	PHASE1/PHASE2	WITHDRAWN
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	UNKNOWN
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy	PHASE2	RECRUITING
Study of AD128 Versus Placebo in Obstructive Sleep Apnea	PHASE2	COMPLETED
Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment	PHASE1	COMPLETED
Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer	PHASE1	COMPLETED
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833	PHASE1	COMPLETED
Study of FCN-098 in Patients With Advanced Solid Tumor	PHASE1	UNKNOWN
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)	PHASE1	RECRUITING
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma	PHASE1	COMPLETED
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients	PHASE1	COMPLETED
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST	PHASE1	COMPLETED
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer	PHASE1	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CYP2C8 binder may also engage these)

Protein	Name	Similarity
Q08078	—	1.000	Q08078 →
P33262	—	1.000	P33262 →
P33263	—	1.000	P33263 →
P56656	—	1.000	P56656 →
Q64458	—	1.000	Q64458 →
P33264	—	1.000	P33264 →
CYP2C19	Cytochrome P450 2C19	1.000	landscape →
P05179	—	1.000	P05179 →
P15123	—	1.000	P15123 →
P33265	—	1.000	P33265 →
P00181	—	1.000	P00181 →
P17666	—	1.000	P17666 →
P00180	—	1.000	P00180 →
P11372	—	0.998	P11372 →
P08683	—	0.998	P08683 →
P33273	—	0.998	P33273 →
P20812	—	0.997	P20812 →
CYP2C18	Cytochrome P450 2C18	0.996	landscape →
CYP2C9	Cytochrome P450 2C9	0.996	landscape →
P56655	—	0.996	P56655 →
P00179	—	0.996	P00179 →
CYP2A7	Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7)	0.995	landscape →
P56654	—	0.994	P56654 →
Q64583	—	0.994	Q64583 →
P20852	—	0.993	P20852 →
CYP2A13	Cytochrome P450 2A13	0.993	landscape →
P05178	—	0.993	P05178 →
Q9D816	—	0.992	Q9D816 →
Q91X77	—	0.992	Q91X77 →
O55071	—	0.991	O55071 →